This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (195)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Veterans Administration Study No. 75

Leo R. Zacharski, MD; William G. Henderson, PhD; Frederick R. Rickles, MD; Walter B. Forman, MD; C. J. Cornell, Jr, MD; R. Jackson Forcier, MD; Richard Edwards, MD; Elwood Headley, MD; Sang-Hee Kim, MD; Joseph R. O'Donnell, MD; Robert O'Dell, MD; Karl Tornyos, MD; Hau C. Kwaan, MD

JAMA. 1981;245(8):831-835.

Abstract
In a controlled, randomized study, survival of patients with small cell carcinoma of the lung (SCCL) was prolonged on addition of warfarin sodium to combination chemotherapy plus radiation therapy. Median survival for 25 control patients was 24 weeks and for 25 warfarin-treated patients was 50 weeks. This difference could not be accounted for by differences between groups in performance status, extent of disease, age, or sex. The survival advantage associated with warfarin administration was observed both for patients with extensive disease and for those who failed to achieve complete or partial remission. The warfarin-treated group also demonstrated a significantly increased time to first evidence of disease progression. These results suggest that warfarin may be useful in the treatment of SCCL and also support the hypothesis that the blood coagulation mechanism may be involved in the growth and spread of cancer in man.

(JAMA 1981;245:831-835)

Author Affiliations
From the Veterans Administration Medical Center, White River Junction, Vt (Drs Zacharski and O'Donnell); the Department of Medicine, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Hanover, NH (Drs Zacharski, Cornell, Forcier, and O'Donnell); the Cooperative Studies Program Coordinating Center, VA Medical Center, Hines, III, and the Department of Clinical Pharmacology and Therapeutics, Loyola University School of Medicine, Maywood, III (Dr Henderson); the VA Medical Center, Newington, Conn, and the Department of Medicine, University of Connecticut, School of Medicine, Farmington (Drs Rickles and Edwards); the VA Medical Center and the Department of Medicine and Pharmacology, Case Western Reserve University School of Medicine, Cleveland (Dr Forman): the VA Medical Center, Gainesville, Fla, and Florida State University Medical School, Tallahassee (Dr Headley); the VA Medical Center and the University of Cincinnati Medical School, Cincinnati (Dr Kim); VA Medical Center and the Medical University of South Carolina, Charleston (Dr O'Dell); VA Medical Center and Tulane University Medical School, New Orleans (Dr Tornyos); and VA Medical Center-Lakeside, Chicago, and Northwestern University Medical School, Evanston, III (Dr Kwaan).

Footnotes
Reprint requests to Veterans Administration Medical Center, White River Junction, VT 05001 (Dr Zacharski).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer
Falanga et al.
Am Soc Clin Oncol Ed Book 2008;2008:258-268.
ABSTRACT | FULL TEXT  

Selectin Blocking Activity of a Fucosylated Chondroitin Sulfate Glycosaminoglycan from Sea Cucumber: EFFECT ON TUMOR METASTASIS AND NEUTROPHIL RECRUITMENT
Borsig et al.
J. Biol. Chem. 2007;282:14984-14991.
ABSTRACT | FULL TEXT  

Randomized Comparison of Low Molecular Weight Heparin and Coumarin Derivatives on the Survival of Patients With Cancer and Venous Thromboembolism
Lee et al.
JCO 2005;23:2123-2129.
ABSTRACT | FULL TEXT  

Dicoumarol: A Unique Microtubule Stabilizing Natural Product that Is Synergistic with Taxol
Madari et al.
Cancer Res. 2003;63:1214-1220.
ABSTRACT | FULL TEXT  

Prognosis of Cancers Associated with Venous Thromboembolism
Sorensen et al.
NEJM 2000;343:1846-1850.
ABSTRACT | FULL TEXT  

A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer
Chen et al.
JNCI J Natl Cancer Inst 2000;92:1601-1607.
ABSTRACT | FULL TEXT  

Incidence of Cancer after Prophylaxis with Warfarin against Recurrent Venous Thromboembolism
Schulman et al.
NEJM 2000;342:1953-1958.
ABSTRACT | FULL TEXT  

Cancer, Coagulation, and Anticoagulation
Letai and Kuter
The Oncologist 1999;4:443-449.
ABSTRACT | FULL TEXT  

State-of-the-Art Review : Chemotherapy and Thrombosis in Gynecologic Malignancy
von Tempelhoff et al.
CLIN APPL THROMB HEMOST 1999;5:92-104.
 

Inhibition of Metastases by Anticoagulants
Hejna et al.
JNCI J Natl Cancer Inst 1999;91:22-36.
ABSTRACT | FULL TEXT  

Therapeutic Management of Small Cell Lung Cancer: Fewer Toxic Reactions With Lower Chemotherapeutic Drug Dosages
Kessinger et al.
JAMA 1983;250:3188-3191.
ABSTRACT  

Warfarin and Cancer
ZACHARSKI
ANN INTERN MED 1982;97:784-784.
ABSTRACT  

Antithrombotic Therapy for Cancer
ZACHARSKI
ANN INTERN MED 1982;96:258-258.
ABSTRACT